Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCV Booster Schedules for NT Indigenous Infants
NCT01735084Phase 4Completed
- Sponsor
- Menzies School of Health Research
- Start
- Mar 2013
- Primary completion
- Feb 2019
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of 10-valent pneumococcal conjugate vaccine in invasive pneumococcal disease (IPD), otitis media, pneumonia and 1 more (2 arms), sponsored by Menzies School of Health Research. Primary endpoint: Immune response at 18 months. Started Mar 2013; status: completed.
02
Drugs
10-valent pneumococcal conjugate vaccine
03
Conditions
invasive pneumococcal disease (IPD)otitis mediapneumoniarespiratory tract infection (RTI)
Beyond the preview
Go deeper on NCT01735084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01735084.